Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer

PLoS One. 2016 Feb 9;11(2):e0148186. doi: 10.1371/journal.pone.0148186. eCollection 2016.

Abstract

Background: Cytokines and chemokines in the tumor microenvironment drive metastatic development and their serum levels might mirror the ongoing inflammatory reaction at the tumor site. Novel highly sensitive tools are needed to identify colorectal cancer patients at high risk of recurrence that should be more closely monitored during post-surgical follow up. Here we study whether circulating inflammatory markers might be used to predict recurrence in CRC patients.

Methods: Circulating levels of the inflammatory cytokines IL-1, IL-6, IL-10, TNFalpha, CCL2, CXCL8, VEGF and the acute phase protein Pentraxin-3 were measured by ELISA in preoperative serum samples prospectively collected from a cohort of sixty-nine patients undergoing surgical resection for stage 0-IV CRC and associated with post-operative disease recurrence.

Results: Cox multivariate analysis showed that combined high levels (≥ROC cut off-value) of CXCL8, VEGF and Pentraxin3 were associated with increased risk of disease recurrence [HR: 14.28; 95%CI: (3.13-65.1)] independently of TNM staging. Kaplan-Meier analysis showed that CXCL8, VEGF and Pentraxin3 levels were significantly associated with worse survival (P<0.001).

Conclusions: Circulating inflammatory mediators efficiently predicted postoperative recurrence after CRC surgery. Therefore, this study suggest that their validation in large-scale clinical trials may help in tailoring CRC post-surgical management.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / surgery
  • Female
  • Follow-Up Studies
  • Humans
  • Inflammation Mediators / blood*
  • Male
  • Neoplasm Staging
  • Postoperative Period
  • Prognosis
  • Recurrence

Substances

  • Biomarkers, Tumor
  • Inflammation Mediators

Grants and funding

The work was supported by 16230 Associazione Italiana per la ricerca sul cancro to GDC. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.